ATRA
Price
$13.74
Change
+$0.28 (+2.08%)
Updated
Nov 19 closing price
Capitalization
98.96M
Intraday BUY SELL Signals
INVA
Price
$21.27
Change
-$0.60 (-2.74%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
1.59B
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATRA vs INVA

Header iconATRA vs INVA Comparison
Open Charts ATRA vs INVABanner chart's image
Atara Biotherapeutics
Price$13.74
Change+$0.28 (+2.08%)
Volume$39.55K
Capitalization98.96M
Innoviva
Price$21.27
Change-$0.60 (-2.74%)
Volume$30.58K
Capitalization1.59B
ATRA vs INVA Comparison Chart in %
ATRA
Daily Signal:
Gain/Loss:
INVA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATRA vs. INVA commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATRA is a Hold and INVA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ATRA: $13.73 vs. INVA: $21.27)
Brand notoriety: ATRA and INVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATRA: 66% vs. INVA: 100%
Market capitalization -- ATRA: $98.96M vs. INVA: $1.59B
ATRA [@Biotechnology] is valued at $98.96M. INVA’s [@Biotechnology] market capitalization is $1.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATRA’s FA Score shows that 0 FA rating(s) are green whileINVA’s FA Score has 0 green FA rating(s).

  • ATRA’s FA Score: 0 green, 5 red.
  • INVA’s FA Score: 0 green, 5 red.
According to our system of comparison, INVA is a better buy in the long-term than ATRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATRA’s TA Score shows that 5 TA indicator(s) are bullish while INVA’s TA Score has 6 bullish TA indicator(s).

  • ATRA’s TA Score: 5 bullish, 5 bearish.
  • INVA’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, INVA is a better buy in the short-term than ATRA.

Price Growth

ATRA (@Biotechnology) experienced а +10.06% price change this week, while INVA (@Biotechnology) price change was -4.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

INVA is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INVA($1.59B) has a higher market cap than ATRA($99M). INVA has higher P/E ratio than ATRA: INVA (13.18) vs ATRA (4.80). INVA YTD gains are higher at: 22.594 vs. ATRA (3.118). INVA has higher annual earnings (EBITDA): 112M vs. ATRA (14.3M). INVA has more cash in the bank: 498M vs. ATRA (22.3M). ATRA has less debt than INVA: ATRA (17.7M) vs INVA (451M). INVA has higher revenues than ATRA: INVA (370M) vs ATRA (189M).
ATRAINVAATRA / INVA
Capitalization99M1.59B6%
EBITDA14.3M112M13%
Gain YTD3.11822.59414%
P/E Ratio4.8013.1836%
Revenue189M370M51%
Total Cash22.3M498M4%
Total Debt17.7M451M4%
FUNDAMENTALS RATINGS
ATRA vs INVA: Fundamental Ratings
ATRA
INVA
OUTLOOK RATING
1..100
621
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
10037
SMR RATING
1..100
10080
PRICE GROWTH RATING
1..100
4142
P/E GROWTH RATING
1..100
9890
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INVA's Valuation (60) in the Pharmaceuticals Other industry is in the same range as ATRA (66) in the Biotechnology industry. This means that INVA’s stock grew similarly to ATRA’s over the last 12 months.

INVA's Profit vs Risk Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for ATRA (100) in the Biotechnology industry. This means that INVA’s stock grew somewhat faster than ATRA’s over the last 12 months.

INVA's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as ATRA (100) in the Biotechnology industry. This means that INVA’s stock grew similarly to ATRA’s over the last 12 months.

ATRA's Price Growth Rating (41) in the Biotechnology industry is in the same range as INVA (42) in the Pharmaceuticals Other industry. This means that ATRA’s stock grew similarly to INVA’s over the last 12 months.

INVA's P/E Growth Rating (90) in the Pharmaceuticals Other industry is in the same range as ATRA (98) in the Biotechnology industry. This means that INVA’s stock grew similarly to ATRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATRAINVA
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 2 days ago
59%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 2 days ago
68%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 2 days ago
67%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 2 days ago
57%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 2 days ago
58%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 8 days ago
65%
Declines
ODDS (%)
Bearish Trend 15 days ago
86%
Bearish Trend 2 days ago
62%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 2 days ago
54%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 2 days ago
54%
View a ticker or compare two or three
Interact to see
Advertisement
ATRA
Daily Signal:
Gain/Loss:
INVA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HIAOX19.58N/A
N/A
Hartford International Opp HLS IA
VFSNX265.78N/A
N/A
Vanguard FTSE All-Wld ex-US SmCp Idx Ins
IICAX12.15N/A
N/A
AMF Large Cap Equity AMF
PVEJX15.62N/A
N/A
Principal MidCap Value I J
ANVIX27.68-0.06
-0.22%
Virtus NFJ Large-Cap Value Fund Inst

INVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, INVA has been loosely correlated with DTIL. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if INVA jumps, then DTIL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INVA
1D Price
Change %
INVA100%
-2.74%
DTIL - INVA
34%
Loosely correlated
-7.66%
ATRA - INVA
31%
Poorly correlated
+1.97%
KNSA - INVA
31%
Poorly correlated
+2.10%
MCRB - INVA
31%
Poorly correlated
+15.86%
SLNO - INVA
30%
Poorly correlated
-3.21%
More